Fluphenazine decanoate dihydrochloride
Modify Date: 2025-08-25 12:33:25
Fluphenazine decanoate dihydrochloride structure
|
Common Name | Fluphenazine decanoate dihydrochloride | ||
|---|---|---|---|---|
| CAS Number | 2376-65-0 | Molecular Weight | 664.693 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C32H46Cl2F3N3O2S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Fluphenazine decanoate dihydrochlorideFluphenazine decanoate dihydrochloride is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research[1][2][3]. |
| Name | 2-(4-{3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl}-1-piperazinyl)ethyl decanoate dihydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Fluphenazine decanoate dihydrochloride is a dopamine D2 receptor inhibitor, is a long-acting phenothiazine neuroleptic. Fluphenazine can be used for schizophrenia research[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
D2 Receptor |
| In Vitro | Fluphenazine decanoate dihydrochloride shows activity against T. gondii in human fibroblast cell cultures with an IC50 value of 1.7 mM[1]. |
| In Vivo | Fluphenazine decanoate dihydrochloride (0.22 mg/kg and followed by 0.33 mg/kg; i.m.; 8 times every 3 weeks), as an antipsychotic, increases sensitivity to dopamine on monkey model following extended treatment[2]. Fluphenazine decanoate dihydrochloride (25 mg/kg; i.m.; 6 times every 3 weeks; 24 weeks) induces mouth movements in the rat, serves as a pharmacological model of human tardive dyskinesia[3]. Fluphenazine decanoate dihydrochloride (1, 2, 3 mg/kg/d; s.c.; 60 d) shows antifertility effects and induces hyperprolactinemia concomitant with gonadotropin suppression in adult male rat[4]. Animal Model: Cebus apella monkey[2] Dosage: 0.22 mg/kg and followed by 0.33 mg/kg Administration: Intramuscular injection; 8 times per 3 weeks; 0.22 mg/kg for 63 weeks and 0.33 mg/kg for 6 weeks Result: Decreased the aggressiveness composite behavioral variables (CBV). Resulted stereotypic behavior induced by agonist and decreased prolactin response to AMPH. Animal Model: Male Sprague-Dawley rats (250 g)[3] Dosage: 25 mg/kg Administration: Intramuscular injection into the hind limb; 24 weeks Result: Resulted in spontaneous vacuous chewing mouth movements and jaw tremor. Animal Model: Adult male rats[4] Dosage: 1, 2, 3 mg/kg/d Administration: Subcutaneous injection between 10:00-12:00 h; 60 days Result: Increased serum prolactin level and suppressed serum LH and FSH levels at day 60. Increased hypothalamic tyrosine hydroxylase levels, enhanced chromatin decondensation, and resulted DNA denaturation. |
| References |
| Molecular Formula | C32H46Cl2F3N3O2S |
|---|---|
| Molecular Weight | 664.693 |
| Exact Mass | 663.263977 |
| InChIKey | IJIYWOFSPALWMA-UHFFFAOYSA-N |
| SMILES | CCCCCCCCCC(=O)OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1.Cl.Cl |
| RIDADR | UN 2811 6.1 / PGII |
|---|
| Decanoic acid, 2-[4-[3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester, hydrochloride (1:2) |
| 2-(4-{3-[2-(Trifluoromethyl)-10H-phenothiazin-10-yl]propyl}-1-piperazinyl)ethyl decanoate dihydrochloride |